Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Citi initiates BridgeBio Pharma at Neutral, citing competitive risks despite strong drug sales.
BBIO
$82.33
-$1.77 -2.10%

Citi initiates BridgeBio Pharma at Neutral, citing competitive risks despite strong drug sales.

Analyst Insights
19 May 2026
24/7 Wall Street
View Source
Neutral
pluang ai news

Citi initiated coverage of BridgeBio Pharma with a Neutral rating, highlighting a cautious stance on the company's ATTR-CM drug Attruby amid strong commercial growth. While BridgeBio's lead drug shows rapid sales growth and the company plans multiple new drug applications in 2026, Citi notes significant competition from Pfizer's established tafamidis franchise and execution risks. The rating contrasts with Citi's Buy ratings on other gene-targeted biotechs, reflecting concerns about BridgeBio's competitive position. Investors should consider moderate exposure given the biotech volatility and upcoming competitive data expected in 2026.

More News (BBIO)

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma remains a strong buy due to regulatory approvals for its drug acoramidis and positive clinical data for infigratinib in achondroplasia. The company expects $180.6 million in U.S. net product revenue by Q1 2026 and targets a $2.9 bill...

Analyst Insights
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App